Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.
Blood
; 140(23): 2443-2450, 2022 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772005
3.
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(1D): e240001, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244272
4.
External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
Br J Haematol
; 201(2): 280-284, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36604838
5.
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(1): 67-81, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652935
6.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(12): 1281-1301, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38081133
7.
Electrical Dyssynchrony in Cardiac Amyloidosis: Prevalence, Predictors, Clinical Correlates, and Outcomes.
J Card Fail
; 28(12): 1664-1672, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35882259
8.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
9.
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
Br J Haematol
; 193(6): 1213-1219, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33997961
10.
Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma.
Br J Haematol
; 189(6): 1136-1140, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32012228
11.
Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma.
Br J Haematol
; 189(6): 1074-1082, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32108328
12.
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Hematol Oncol
; 38(3): 353-362, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32053229
13.
Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
Am J Hematol
; 94(4): 439-445, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30663805
14.
Daratumumab monotherapy for relapsed POEMS syndrome.
Am J Hematol
; 98(11): E291-E294, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548551
15.
Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?
Blood Cells Mol Dis
; 91: 102595, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34280665
16.
Emerging Advances in the Management of Cardiac Amyloidosis.
Curr Cardiol Rep
; 17(11): 100, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26374453
17.
Daratumumab proves safe and highly effective in AL amyloidosis.
Br J Haematol
; 185(2): 342-344, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29938774
18.
Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series.
Ann Hematol
; 98(10): 2457-2459, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392460
19.
Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.
JCO Oncol Pract
; 20(5): 699-707, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354331
20.
Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma.
Transplant Cell Ther
; 30(3): 298-305, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142943